Clinical Trial Update: Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a single-dose ketamine treatment to improve depressive symptoms in individuals with mild cognitive impairment; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Major Depressive Disorder

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Depression, Mild Cognitive Impairment | Phase 2 | Status: ACTIVE_NOT_RECRUITING